STAAR Surgical prelim Q1 2026 net sales expected >$90M, up from $42.6M YoY

STAAR SURGICAL CO

2026-Q1 EPS reported $0.10 vs consensus -$0.07 ▲ beat (+253.8%)

Net sales expected to exceed $90M in Q1 2026, more than double prior year's $42.6M.
China accounted for majority of increase; Americas delivered double-digit growth.
Significant cost-structure improvement expected to drive meaningful adjusted EBITDA increase.
Middle East & parts of EMEA/APAC saw sales decline due to geopolitical/macro headwinds.
Full Q1 results and 10-Q to be reported in early May; no forward guidance provided.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.